FT

Johnson & Johnson to buy biotech Momenta in $6.5bn deal

Tie-up is latest example of a big pharma group seeking to bolster rare disease portfolio

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button